Seres Therapeutics' Microbiome Therapeutic Advancements

Seres Therapeutics presents preliminary data for SER-155, an investigational microbiome therapeutic, to prevent enteric-derived infections and reduce graft-versus-host disease in allo-HCT patients. The company aims to modulate immune responses and restructure the microbiome to reduce pathogen translocation and bloodstream infection. VOWST™, derived from SER-155, has obtained FDA approval for CDI prevention and is being commercialized with Nestlé Health Science.